Kenvue Inc. (NYSE:KVUE) Stake Boosted by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lifted its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 272,497 shares of the company's stock after buying an additional 19,042 shares during the period. Daiwa Securities Group Inc.'s holdings in Kenvue were worth $5,818,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Alerus Financial NA boosted its position in shares of Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company's stock worth $4,426,000 after buying an additional 491 shares during the period. Kiley Juergens Wealth Management LLC lifted its position in Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock worth $579,000 after purchasing an additional 500 shares during the period. Principle Wealth Partners LLC lifted its position in Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock worth $303,000 after purchasing an additional 500 shares during the period. White Pine Capital LLC lifted its position in Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock worth $1,165,000 after purchasing an additional 542 shares during the period. Finally, Deseret Mutual Benefit Administrators lifted its position in Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after purchasing an additional 568 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of Kenvue stock opened at $23.09 on Thursday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $44.12 billion, a PE ratio of 43.56, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The business has a fifty day simple moving average of $21.77 and a 200-day simple moving average of $22.37.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.55%. The ex-dividend date was Wednesday, February 12th. Kenvue's payout ratio is presently 154.72%.

Analysts Set New Price Targets

A number of research firms have weighed in on KVUE. Canaccord Genuity Group upped their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and cut their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Barclays cut their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Finally, UBS Group reduced their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.